Final 5-year results of the phase III TRIPLETE trial in 435 patients with RAS/BRAF wild-type mCRC: mFOLFOXIRI/panitumumab did not improve response rate (primary; 75% vs 78%) over mFOLFOX/panitumumab, but median OS was 41.1 vs 33.3 months (HR 0.79).
RCTn = 435
Conca et al. Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study